## **Empowering Women:**PrEP for HIV Prevention

In 2022, there were **4,882 new HIV diagnoses** in **California**. **13%** were **cisgender** women and **3%** were **trans** women.<sup>1</sup>




One in six new HIV diagnoses are among women<sup>1</sup>



Most HIV diagnoses among women are from sexual contact<sup>1</sup>

## Women of Color are Disproportionately Impacted by HIV in California

Rate of New HIV Diagnoses Among Cisgender Women by Race/Ethnicity, 2022



In 2022, the rate among Black/African American women was 5.7 times that of White women.

Number of New HIV Diagnoses Among Women by Race/Ethnicity, 2022<sup>1</sup>




In 2022, Latinx trans women represented roughly 67% of trans women newly diagnosed with HIV.

PrEPa

**Pre-Exposure Prophylaxis (PrEP)** is the use of antiretroviral medication to **prevent HIV**. PrEP is for people without HIV who may be exposed to HIV through sex or injection drug use.


## Women Have an Unmet Need for PrEP

In 2023, only 6% of all PrEP users in California were female, despite the fact that cisgender women represented 13% of new HIV diagnoses in 2022.<sup>2</sup>



## Glinical Guidance for PrEPs 3

- Inform all sexually active adult and adolescent patients about PrEP.
- Prescribe PrEP to anyone who asks for it, including sexually active people who do not report HIV risk factors.
- Offer PrEP medication and methods of administration to meet patients' needs.



\*Acronyms: NH/PI = Native Hawaiian/Pacific Islander; AI/AN = American Indian/ Alaskan Native; AA = African American • References: ¹California Department of Public Health, Office of AIDS, California HIV Surveillance Data 2022; ²AIDSVu. org ³Centers for Disease Control and Prevention, HIV Nexus, Clinical Guidance for PrEP • Additional Resources on Women, PrEP, and HIV • This material was developed by the California Planning Group.

